In low-grade gliomas (LGGs), elevated mRNA levels of TGFB2 emerged as a significant negative prognostic marker, particularly when coupled with the activation of interferon-gamma receptor signaling via interferon regulatory factor 5 (IRF5) and the increased expression of the immune checkpoint molecule B7-H3 [12]. The gene discussed is IRF5; the disease is low grade glioma.